⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Biohaven Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Biohaven Ltd.
↗New Haven, USA
Biohaven Ltd. is a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies for patients with debilitating diseases. The company leverages proprietary platforms in areas such as extracellular protein degradation (MoDE and TRAP), ion channel modulation, and antibody-drug conjugates (ADCs) to address significant unmet medical needs in neuroscience, immunology, and oncology.
Following the 2022 acquisition of its former migraine franchise by Pfizer, Biohaven has repositioned itself as a research-driven entity with a robust pipeline of early- and late-stage assets. The company maintains a patient-first culture and operates with an entrepreneurial structure, focusing on high-value, innovative science to improve outcomes in conditions ranging from rare genetic disorders to common immune-mediated diseases.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Neuroscience, Immunology, Oncology
SIZE & FINANCIALS
Employees:501-1000
Founded:2013
Ownership:public
Status:operating
STOCK
Exchange:NYSE
Ticker:BHVN
Market Cap:$1.46B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule, ADC, Protein degraders (MoDE/TRAP), Recombinant proteins
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Regeneron (Clinical supply agreement for BHV-1510 combination study)
COMPETITION
Position:Challenger
Competitors:Gilead Sciences, Regeneron, Amicus Therapeutics
LEADERSHIP
Key Executives:
Vlad Coric - Chairman and CEO
LINKS
Website:biohavenpharma.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Biohaven Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.